Placebo-controlled, randomized clinical trial of high-dose cholecalciferol in renal dialysis patients: effect on muscle strength and quality of life
Singer R, Chacko B, Talaulikar G, Karpe K, Walters G
Clinical kidney journal · 18 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Canberra Hospital Private Practice Fund
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-04-24 · Clin Kidney J · vol. 12 · número 2 · págs. 281–287
- Editorial
- Oxford University Press
- Citado
- 20 citas · más que el 62% de estudios similares · 0.5× el promedio de su campo
- Referencias
- 25 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Dialysis and Renal Disease Management
- Palabras clave
- Medicine, Cholecalciferol, Placebo, Vitamin D and neurology, Randomized controlled trial, Internal medicine, Grip strength, Dialysis, Kidney disease, Adverse effect, Confidence interval, Parathyroid hormone, Gastroenterology, Urology, Surgery, Calcium
5 autores
- Richard Francis Singer🇦🇺 · autor de correspondenciaAustralian National University; Canberra Hospital
- Bobby Chacko🇦🇺John Hunter Hospital; University of Newcastle Australia
- Girish Sricant Talaulikar🇦🇺Australian National University; Canberra Hospital
- Krishna M Karpe🇦🇺Australian National University; Canberra Hospital
- Giles Desmond Walters🇦🇺Australian National University; Canberra Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The importance of vitamin D sufficiency in deficient dialysis patients is uncertain. This study aimed to determine if high-dose cholecalciferol for 1-year affected symptoms, muscle strength, blood pressure (BP), cardiac ischaemia, parathyroid hormone, calcium or phosphate.
Methods
This was a randomized, double-blind, placebo-controlled trial with 1-year follow-up that enrolled dialysis patients with 25-hydroxy-vitamin D [25(OH)D] concentration 80 nmol/L. The primary objectives were to assess the effect of supplementation on renal-specific symptoms and on hand-grip strength. Symptoms were assessed using the Kidney Disease Quality of Life Short Form and muscle strength with a hand grip-strength dynamometer. Hypothesis testing was by two-group t-test and Wilcoxon rank-sum on an intention-to-treat basis.
Results
In all, 68 participants were randomized and received study medication. Median 12-month plasma 25(OH)D concentration was 119 nmol/L and 37 nmol/L in the cholecalciferol and placebo groups, respectively. There was no statistical difference in primary outcomes at 12 months. Mean symptom scores at 12 months were two lower in the cholecalciferol group (95% confidence interval -10 to 6) and geometric mean grip-strength was 27 kg in both groups. Symptoms, strength, BP, plasma mineral bone parameters and adverse events were not different between the groups at follow-up.
Conclusions
High-dose cholecalciferol in a deficient dialysis population had no effect on muscle strength or symptoms but appears safe.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.